Regional disease specific incidence of WHO stage 3 conditions in months 0–3 following ART initiation.

Total number of outbreaks for selected diseases during 2010 to 2015 in four member countries.

Saranath Lawpoolsri (305283)
Jaranit Kaewkungwal (190918)
Amnat Khamsiriwatchara (3409763)
Ly Sovann (292625)
Bun Sreng (5143130)
Bounlay Phommasack (5143133)
Viengsavanh Kitthiphong (5143121)
Soe Lwin Nyein (5143127)
Nyan Win Myint (5143139)
Nguyen Dang Vung (44106)
Pham Hung (5143136)
Mark S. Smolinski (5143124)
Adam W. Crawley (484495)
Moe Ko Oo (5143118)

April 2018

Total number of outbreaks for selected diseases during 2010 to 2015 in four member countries.</p

Cumulative incidence after month-12 visit of renal event (panel A) and all-cause death before ESRD (panel B).

Luca De Nicola (741533)
Michele Provenzano (741534)
Paolo Chiodini (586278)
Silvio Borrelli (451490)
Carlo Garofalo (741535)
Mario Pacilio (741536)
Maria Elena Liberti (741537)
Adelia Sagliocca (741538)
Giuseppe Conte (741539)
Roberto Minutolo (741540)

May 2015

Cumulative incidence after month-12 visit of renal event (panel A) and all-cause death before ESR...

Patients’ status 12 months after ART initiation by type of facility (N = 19,927).

Yves Lafort (3141786)
Aleny Couto (3374306)
Ute Sunderbrink (5435330)
Roxanne Hoek (5435333)
Estifanos Shargie (141068)
Jinkou Zhao (141062)
Kirsi Viisainen (216141)
Bertha Simwaka (3541235)

June 2018

Patients’ status 12 months after ART initiation by type of facility (N = 19,927).</p

Regional disease specific incidence of WHO stage 4 conditions in months 0–3 following ART initiation.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

Regional disease specific incidence of WHO stage 4 conditions in months 0–3 following ART initiat...

Disease specific Incidence of WHO stage 3 conditions in months 0–3 following ART initiation by age.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

Disease specific Incidence of WHO stage 3 conditions in months 0–3 following ART initiation by ag...

Disease specific Incidence of WHO stage 4 conditions in months 0–3 following ART initiation by age.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

Disease specific Incidence of WHO stage 4 conditions in months 0–3 following ART initiation by ag...

Disease specific incidence over 36 months for selected WHO Stage 3 conditions.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

*n = the number of patients who were followed up for the entire time period indicated.</p

Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings

Andrea J Marshall
Catherine S Spelman
Jane Elliot
Julian H Shanks
Leslie Du Cros
Esther C Da Fonseca
Marcio Silveria
O&apos
Andrea J. Curtis
Catherine S. Marshall
Tim Spelman
Jane Greig
Julian H. Elliot
Leslie Shanks
Esther C. Casas
Marcio Silveria
Da Fonseca
Daniel P. O’brien

September 2016

Citation Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy i...

Disease specific incidence over 36 months for selected WHO Stage 4 conditions.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

*n = the number of patients who were followed up for the entire time period indicated.</p

Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings

Curtis Andrea J.
Marshall Catherine S.
Spelman Tim
Greig Jane
Elliot Julian H.
Shanks Leslie
Du Cros Philipp
Casas Esther C.
Da Fonseca Marcio Silveria
O’Brien Daniel P.

December 2012

To determine the incidence of WHO clinical stage 3 and 4 conditions during early anti-retroviral the...

Cumulative incidence of mortality up to four years after start of ART by region, corrected in South Africa for mortality under-ascertainment.

Andrew Boulle (93997)
Michael Schomaker (138489)
Margaret T. May (627545)
Robert S. Hogg (118028)
Bryan E. Shepherd (173791)
Susana Monge (437404)
Olivia Keiser (93991)
Fiona C. Lampe (470943)
Janet Giddy (25207)
James Ndirangu (291392)
Daniela Garone (383442)
Matthew Fox (361722)
Suzanne M. Ingle (627546)
Peter Reiss (4933)
Francois Dabis (3141000)
Dominique Costagliola (131086)
Antonella Castagna (255402)
Kathrin Ehren (627547)
Colin Campbell (527529)
M. John Gill (341799)
Michael Saag (170633)
Amy C. Justice (229955)
Jodie Guest (627548)
Heidi M. Crane (627549)
Matthias Egger (24558)
Jonathan A. C. Sterne (123321)

September 2014

Cumulative incidence of mortality up to four years after start of ART by region, corrected in Sou...

Cumulative incidence of mortality up to four years after start of ART by region and CD4 count at ART initiation, corrected in South Africa for mortality under-ascertainment.

Andrew Boulle (93997)
Michael Schomaker (138489)
Margaret T. May (627545)
Robert S. Hogg (118028)
Bryan E. Shepherd (173791)
Susana Monge (437404)
Olivia Keiser (93991)
Fiona C. Lampe (470943)
Janet Giddy (25207)
James Ndirangu (291392)
Daniela Garone (383442)
Matthew Fox (361722)
Suzanne M. Ingle (627546)
Peter Reiss (4933)
Francois Dabis (3141000)
Dominique Costagliola (131086)
Antonella Castagna (255402)
Kathrin Ehren (627547)
Colin Campbell (527529)
M. John Gill (341799)
Michael Saag (170633)
Amy C. Justice (229955)
Jodie Guest (627548)
Heidi M. Crane (627549)
Matthias Egger (24558)
Jonathan A. C. Sterne (123321)

September 2014

Cumulative incidence of mortality up to four years after start of ART by region and CD4 count at ...

Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings

Curtis, AJ
Marshall, CS
Spelman, T
Greig, J
Elliot, JH
Shanks, L
Du Cros, P
Casas, EC
Da Fonseca, MS
O'Brien, DP

December 2012

OBJECTIVES: To determine the incidence of WHO clinical stage 3 and 4 conditions during early anti-re...

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clinical stage (left) and CD4 cell count (right).

Fabienne Shumbusho (369912)
Johan van Griensven (333866)
David Lowrance (318136)
Innocent Turate (369913)
Mark A. Weaver (369914)
Jessica Price (369915)
Agnes Binagwaho (26709)

February 2013

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clin...

Kaplan-Meier survival analysis comparing those with a diagnosis of any WHO stage 3 or 4 condition within the first 6 months after ART initiation and those without.

Catherine S. Marshall (293084)
Andrea J. Curtis (293082)
Tim Spelman (143159)
Daniel P. O’Brien (293088)
Jane Greig (168891)
Leslie Shanks (140067)
Philipp du Cros (168905)
Esther C. Casas (293086)
Marcio Silveira da Fonseca (168902)
Eugene Athan (188019)
Julian H. Elliott (281412)

July 2013

Kaplan-Meier survival analysis comparing those with a diagnosis of any WHO stage 3 or 4 condition...

Total number of outbreaks for selected diseases during 2010 to 2015 in four member countries.

Saranath Lawpoolsri (305283)
Jaranit Kaewkungwal (190918)
Amnat Khamsiriwatchara (3409763)
Ly Sovann (292625)
Bun Sreng (5143130)
Bounlay Phommasack (5143133)
Viengsavanh Kitthiphong (5143121)
Soe Lwin Nyein (5143127)
Nyan Win Myint (5143139)
Nguyen Dang Vung (44106)
Pham Hung (5143136)
Mark S. Smolinski (5143124)
Adam W. Crawley (484495)
Moe Ko Oo (5143118)

April 2018

Total number of outbreaks for selected diseases during 2010 to 2015 in four member countries.</p

Cumulative incidence after month-12 visit of renal event (panel A) and all-cause death before ESRD (panel B).

Luca De Nicola (741533)
Michele Provenzano (741534)
Paolo Chiodini (586278)
Silvio Borrelli (451490)
Carlo Garofalo (741535)
Mario Pacilio (741536)
Maria Elena Liberti (741537)
Adelia Sagliocca (741538)
Giuseppe Conte (741539)
Roberto Minutolo (741540)

May 2015

Cumulative incidence after month-12 visit of renal event (panel A) and all-cause death before ESR...

Patients’ status 12 months after ART initiation by type of facility (N = 19,927).

Yves Lafort (3141786)
Aleny Couto (3374306)
Ute Sunderbrink (5435330)
Roxanne Hoek (5435333)
Estifanos Shargie (141068)
Jinkou Zhao (141062)
Kirsi Viisainen (216141)
Bertha Simwaka (3541235)

June 2018

Patients’ status 12 months after ART initiation by type of facility (N = 19,927).</p

Regional disease specific incidence of WHO stage 4 conditions in months 0–3 following ART initiation.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

Regional disease specific incidence of WHO stage 4 conditions in months 0–3 following ART initiat...

Disease specific Incidence of WHO stage 3 conditions in months 0–3 following ART initiation by age.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

Disease specific Incidence of WHO stage 3 conditions in months 0–3 following ART initiation by ag...

Disease specific Incidence of WHO stage 4 conditions in months 0–3 following ART initiation by age.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

Disease specific Incidence of WHO stage 4 conditions in months 0–3 following ART initiation by ag...

Disease specific incidence over 36 months for selected WHO Stage 3 conditions.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

*n = the number of patients who were followed up for the entire time period indicated.</p

Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings

Andrea J Marshall
Catherine S Spelman
Jane Elliot
Julian H Shanks
Leslie Du Cros
Esther C Da Fonseca
Marcio Silveria
O&apos
Andrea J. Curtis
Catherine S. Marshall
Tim Spelman
Jane Greig
Julian H. Elliot
Leslie Shanks
Esther C. Casas
Marcio Silveria
Da Fonseca
Daniel P. O’brien

September 2016

Citation Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy i...

Disease specific incidence over 36 months for selected WHO Stage 4 conditions.

Andrea J. Curtis (293082)
Catherine S. Marshall (293084)
Tim Spelman (143159)
Jane Greig (168891)
Julian H. Elliot (293085)
Leslie Shanks (140067)
Philipp Du Cros (5648524)
Esther C. Casas (293086)
Marcio Silveria Da Fonseca (293087)
Daniel P. O’Brien (293088)

February 2013

*n = the number of patients who were followed up for the entire time period indicated.</p

Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings

Curtis Andrea J.
Marshall Catherine S.
Spelman Tim
Greig Jane
Elliot Julian H.
Shanks Leslie
Du Cros Philipp
Casas Esther C.
Da Fonseca Marcio Silveria
O’Brien Daniel P.

December 2012

To determine the incidence of WHO clinical stage 3 and 4 conditions during early anti-retroviral the...

Cumulative incidence of mortality up to four years after start of ART by region, corrected in South Africa for mortality under-ascertainment.

Andrew Boulle (93997)
Michael Schomaker (138489)
Margaret T. May (627545)
Robert S. Hogg (118028)
Bryan E. Shepherd (173791)
Susana Monge (437404)
Olivia Keiser (93991)
Fiona C. Lampe (470943)
Janet Giddy (25207)
James Ndirangu (291392)
Daniela Garone (383442)
Matthew Fox (361722)
Suzanne M. Ingle (627546)
Peter Reiss (4933)
Francois Dabis (3141000)
Dominique Costagliola (131086)
Antonella Castagna (255402)
Kathrin Ehren (627547)
Colin Campbell (527529)
M. John Gill (341799)
Michael Saag (170633)
Amy C. Justice (229955)
Jodie Guest (627548)
Heidi M. Crane (627549)
Matthias Egger (24558)
Jonathan A. C. Sterne (123321)

September 2014

Cumulative incidence of mortality up to four years after start of ART by region, corrected in Sou...

Cumulative incidence of mortality up to four years after start of ART by region and CD4 count at ART initiation, corrected in South Africa for mortality under-ascertainment.

Andrew Boulle (93997)
Michael Schomaker (138489)
Margaret T. May (627545)
Robert S. Hogg (118028)
Bryan E. Shepherd (173791)
Susana Monge (437404)
Olivia Keiser (93991)
Fiona C. Lampe (470943)
Janet Giddy (25207)
James Ndirangu (291392)
Daniela Garone (383442)
Matthew Fox (361722)
Suzanne M. Ingle (627546)
Peter Reiss (4933)
Francois Dabis (3141000)
Dominique Costagliola (131086)
Antonella Castagna (255402)
Kathrin Ehren (627547)
Colin Campbell (527529)
M. John Gill (341799)
Michael Saag (170633)
Amy C. Justice (229955)
Jodie Guest (627548)
Heidi M. Crane (627549)
Matthias Egger (24558)
Jonathan A. C. Sterne (123321)

September 2014

Cumulative incidence of mortality up to four years after start of ART by region and CD4 count at ...

Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings

Curtis, AJ
Marshall, CS
Spelman, T
Greig, J
Elliot, JH
Shanks, L
Du Cros, P
Casas, EC
Da Fonseca, MS
O'Brien, DP

December 2012

OBJECTIVES: To determine the incidence of WHO clinical stage 3 and 4 conditions during early anti-re...

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clinical stage (left) and CD4 cell count (right).

Fabienne Shumbusho (369912)
Johan van Griensven (333866)
David Lowrance (318136)
Innocent Turate (369913)
Mark A. Weaver (369914)
Jessica Price (369915)
Agnes Binagwaho (26709)

February 2013

Kaplan-Meier plots showing mortality of 435 patients after initiation of ART by baseline WHO clin...

Kaplan-Meier survival analysis comparing those with a diagnosis of any WHO stage 3 or 4 condition within the first 6 months after ART initiation and those without.

Catherine S. Marshall (293084)
Andrea J. Curtis (293082)
Tim Spelman (143159)
Daniel P. O’Brien (293088)
Jane Greig (168891)
Leslie Shanks (140067)
Philipp du Cros (168905)
Esther C. Casas (293086)
Marcio Silveira da Fonseca (168902)
Eugene Athan (188019)
Julian H. Elliott (281412)

July 2013

Kaplan-Meier survival analysis comparing those with a diagnosis of any WHO stage 3 or 4 condition...

Total number of outbreaks for selected diseases during 2010 to 2015 in four member countries.

Saranath Lawpoolsri (305283)
Jaranit Kaewkungwal (190918)
Amnat Khamsiriwatchara (3409763)
Ly Sovann (292625)
Bun Sreng (5143130)
Bounlay Phommasack (5143133)
Viengsavanh Kitthiphong (5143121)
Soe Lwin Nyein (5143127)
Nyan Win Myint (5143139)
Nguyen Dang Vung (44106)
Pham Hung (5143136)
Mark S. Smolinski (5143124)
Adam W. Crawley (484495)
Moe Ko Oo (5143118)

April 2018

Total number of outbreaks for selected diseases during 2010 to 2015 in four member countries.</p

Cumulative incidence after month-12 visit of renal event (panel A) and all-cause death before ESRD (panel B).

Luca De Nicola (741533)
Michele Provenzano (741534)
Paolo Chiodini (586278)
Silvio Borrelli (451490)
Carlo Garofalo (741535)
Mario Pacilio (741536)
Maria Elena Liberti (741537)
Adelia Sagliocca (741538)
Giuseppe Conte (741539)
Roberto Minutolo (741540)

May 2015

Cumulative incidence after month-12 visit of renal event (panel A) and all-cause death before ESR...

Patients’ status 12 months after ART initiation by type of facility (N = 19,927).

Yves Lafort (3141786)
Aleny Couto (3374306)
Ute Sunderbrink (5435330)
Roxanne Hoek (5435333)
Estifanos Shargie (141068)
Jinkou Zhao (141062)
Kirsi Viisainen (216141)
Bertha Simwaka (3541235)

June 2018

Patients’ status 12 months after ART initiation by type of facility (N = 19,927).</p

Regional disease specific incidence of WHO stage 3 conditions in months 0–3 following ART initiation.

Abstract

Extracted data

Regional disease specific incidence of WHO stage 3 conditions in months 0–3 following ART initiation.

Abstract

Extracted data

Related items

Related items